In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

CancerVax and Micromet to merge

Executive Summary

Public oncology company CancerVax and privately held antibody therapeutics firm Micromet AG have agreed to merge to form a new public company with candidates in development for cancer, inflammation, and autoimmune diseases.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Full Acquisition
    • Includes Contract
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register